NIH Reporter #5R01HD110109-04

OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention

This award funds a clinical pharmacokinetic study to determine the optimal timing, route, and dose of tranexamic acid administered prior to umbilical cord clamp to prevent postpartum hemorrhage, aiming to maximize maternal benefit and minimize neonatal risk.

Description

Prevention of postpartum hemorrhage using antifibrinolytic therapy, specifically tranexamic acid, has great potential in the field of obstetrics. The project involves conducting a clinical pharmacokinetic study to find the lowest drug dose needed for optimal hemostasis when tranexamic acid is given prior to delivery, aiming to maximize maternal benefit and minimize fetal/neonatal risk. This translational research is critical to understanding the role of tranexamic acid in preventing postpartum hemorrhage and maternal deaths worldwide.

View original record